Detalles de la búsqueda
1.
Safety and Tolerability of the APOL1 Inhibitor, Inaxaplin, following Single- and Multiple-Ascending Doses in Healthy Adults.
Glomerular Dis;
4(1): 64-73, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38600955
2.
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
Am J Respir Crit Care Med;
209(3): 299-306, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37890129
3.
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
Eur Respir J;
62(6)2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37945033
4.
ScSmOP: a universal computational pipeline for single-cell single-molecule multiomics data analysis.
Brief Bioinform;
24(6)2023 09 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37779245
5.
Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial.
Ann Am Thorac Soc;
20(8): 1144-1155, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36943405
6.
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Lancet Respir Med;
11(6): 550-562, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36842446
7.
MCI-frcnn: A deep learning method for topological micro-domain boundary detection.
Front Cell Dev Biol;
10: 1050769, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36531953
8.
MCIBox: a toolkit for single-molecule multi-way chromatin interaction visualization and micro-domains identification.
Brief Bioinform;
23(6)2022 11 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-36094071
9.
Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment.
Eur J Drug Metab Pharmacokinet;
47(6): 817-825, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36036885
10.
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.
Am J Respir Crit Care Med;
206(11): 1361-1369, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35816621
11.
A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.
Am J Respir Crit Care Med;
206(10): 1239-1247, 2022 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35771568
12.
Rora Regulates Neutrophil Migration and Activation in Zebrafish.
Front Immunol;
13: 756034, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35309302
13.
Pore-C simultaneously captures genome-wide multi-way chromatin interaction and associated DNA methylation status in Arabidopsis.
Plant Biotechnol J;
20(6): 1009-1011, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35313066
14.
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Lancet Respir Med;
10(3): 267-277, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34942085
15.
Nuclear pore protein NUP210 depletion suppresses metastasis through heterochromatin-mediated disruption of tumor cell mechanical response.
Nat Commun;
12(1): 7216, 2021 12 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34903738
16.
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
N Engl J Med;
385(9): 815-825, 2021 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34437784
17.
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.
Lancet Respir Med;
9(9): 977-988, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33965000
18.
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.
Am J Respir Crit Care Med;
203(12): 1522-1532, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33734030
19.
Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
Lancet Respir Med;
9(7): 721-732, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33516285
20.
VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial.
J Cyst Fibros;
20(3): 499-505, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33358691